trial

Neurocognitive Training Integrated in OPUS Treatment Versus OPUS Treatment-as-usual

NCTId NCT00472862
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 117 (actual)
Sponsored by Neurocom
Primary completion 2010-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
117 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2007-01
Primary completion
2010-04
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
Cognitive training

Sponsors

NeurocomLead Sponsor

Investigators

1
Merete Nordentoft, MD, PhD, MPHStudy Chair

Sites

1 total
Copenhagen, Denmark

Linked catalysts

1
Neurocognitive Training Integrated in OPUS Treatment Versus OPUS Treatment-as-us — primary completion2010-04

Facts & assertions

4 sourced
Enrollment
117
Phase
PHASE3
Primary Completion Date
2010-04
Status
COMPLETED
relationships
The graph out of here
drug
Cognitive training
drug
lead_sponsor
Neurocom
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Merete Nordentoft, MD, PhD, MPH
person